Suppliers and packagers for generic pharmaceutical drug: ketoconazole

ketoconazole

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Padagis Israel	KETOCONAZOLE	ketoconazole	AEROSOL, FOAM;TOPICAL	091550	ANDA	Medimetriks Pharmaceuticals, Inc.	43538-530-10	1 CAN in 1 CARTON (43538-530-10) / 100 g in 1 CAN	2012-06-15
Padagis Israel	KETOCONAZOLE	ketoconazole	AEROSOL, FOAM;TOPICAL	091550	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-532-32	1 CANISTER in 1 CARTON (45802-532-32) / 50 g in 1 CANISTER	2011-08-30
Padagis Israel	KETOCONAZOLE	ketoconazole	AEROSOL, FOAM;TOPICAL	091550	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-532-33	1 CANISTER in 1 CARTON (45802-532-33) / 100 g in 1 CANISTER	2011-08-30

Ketoconazole Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for ketoconazole, a synthetic imidazole antifungal agent. The analysis focuses on key suppliers, their manufacturing capabilities, regulatory standing, and potential risks to the pharmaceutical drug supply. Ketoconazole is used to treat a variety of fungal infections, including skin infections like athlete's foot, ringworm, and jock itch, as well as more serious systemic fungal infections. Its long history of use and established efficacy profile contribute to consistent demand.

What are the primary manufacturing hubs for ketoconazole?

The global manufacturing of ketoconazole active pharmaceutical ingredient (API) is concentrated in Asia, with a significant portion originating from China and India. These regions offer cost advantages in API production and have established infrastructure for chemical synthesis. European and North American manufacturers also produce ketoconazole, often focusing on higher-purity grades or for specialized markets.

• China: Dominates API production due to large-scale manufacturing facilities and competitive pricing. Key manufacturing provinces include Jiangsu and Zhejiang.
• India: A major global supplier of APIs, including ketoconazole, with numerous contract manufacturing organizations (CMOs) and in-house API producers.
• Europe: While less dominant in bulk API production, some European companies manufacture ketoconazole, particularly for specific formulations or regions with stringent quality requirements.
• North America: Limited large-scale API production, with some specialized manufacturing or formulation activities.

Which companies are significant suppliers of ketoconazole API?

Several global pharmaceutical ingredient manufacturers supply ketoconazole API. These companies vary in scale, regulatory compliance, and market reach. The selection of a supplier is critical, necessitating due diligence on quality, capacity, and regulatory adherence.

• Symbiotec Pharmachem Pvt. Ltd. (India): A significant producer of various APIs, including ketoconazole. They operate with cGMP compliance and supply to regulated markets.
• Abbott India Limited (India): While primarily a formulator, Abbott India also has API manufacturing capabilities and is a known supplier.
• Divi's Laboratories Limited (India): A large-scale API manufacturer with extensive experience in complex synthesis. While they produce a broad portfolio, their involvement with ketoconazole should be verified for specific supply contracts.
• Hubei Guangji Pharmaceutical Co., Ltd. (China): A major Chinese pharmaceutical manufacturer with a broad API portfolio that includes antifungal agents.
• Zhejiang NHU Co., Ltd. (China): Another significant Chinese player in the API market, with a diverse range of products.
• Shandong Xinhua Pharmaceutical Co., Ltd. (China): A well-established Chinese pharmaceutical company with substantial API manufacturing capacity.
• Bayer AG (Germany): As a historical innovator and marketer of ketoconazole-containing products, Bayer retains significant manufacturing or sourcing operations, though primary API production may be outsourced to third parties.

The specific market share and individual production volumes for ketoconazole API from these companies are proprietary. However, their presence in the market indicates substantial supply capability.

What are the regulatory considerations for ketoconazole API sourcing?

Sourcing ketoconazole API requires adherence to stringent regulatory standards enforced by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory bodies. Compliance with Current Good Manufacturing Practices (cGMP) is paramount.

• cGMP Compliance: Manufacturers must operate under cGMP guidelines to ensure the quality, safety, and efficacy of the API. Audits and inspections by regulatory authorities are common.
• Drug Master Files (DMFs): API suppliers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality control measures. Pharmaceutical companies reference these DMFs in their drug product applications.
• Impurity Profiling: Strict control over impurities is essential. Regulatory agencies set limits for known and unknown impurities, including genotoxic impurities.
• Pharmacopoeial Standards: Ketoconazole API must meet specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
• REACH and Other Chemical Regulations: For API manufactured or imported into the EU, compliance with REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) regulations is also a factor.

What are the potential risks in the ketoconazole supply chain?

Several factors can introduce risk to the ketoconazole supply chain, impacting availability, quality, and cost.

• Geopolitical Instability: Concentration of manufacturing in specific regions, particularly China and India, makes the supply chain vulnerable to trade disputes, export restrictions, or local disruptions.
• Regulatory Changes: Updates to cGMP standards, stricter impurity limits, or new environmental regulations can necessitate process changes or lead to temporary supply interruptions if manufacturers are not compliant.
• Quality Control Failures: Batch failures due to manufacturing errors or contamination can lead to recalls, product shortages, and damage to supplier reputation.
• Raw Material Sourcing: Dependence on specific raw material suppliers can create bottlenecks if those upstream suppliers face disruptions.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can impact production capacity, logistics, and labor availability.
• Intellectual Property and Generic Competition: While ketoconazole is a well-established drug, patent expirations on specific formulations or novel delivery methods could influence market dynamics and the demand for generic API.
• Environmental Scrutiny: Increased focus on environmental impact of chemical manufacturing can lead to stricter regulations, potentially increasing production costs or limiting output for non-compliant facilities.

How does ketoconazole compare to other antifungal APIs in terms of supply chain maturity?

Ketoconazole's supply chain is considered mature, reflecting its long market presence and established manufacturing processes.

• Maturity: Ketoconazole API production has been optimized over decades. Manufacturing processes are well-understood, and a broad base of suppliers exists, contributing to a stable supply.
• Cost: As a mature product, ketoconazole API is generally cost-effective compared to newer or more complex antifungal agents.
• Innovation: While the core API manufacturing is mature, innovation may occur in formulation (e.g., reduced systemic absorption for topical use) or in combination therapies, which indirectly affects API demand.
• Newer Antifungals (e.g., Voriconazole, Posaconazole): These newer agents often involve more complex synthesis, have fewer global manufacturers, and may have less robust supply chains initially. Their supply chains are still evolving as manufacturing scales up and becomes more geographically diversified.
• Fluconazole: Similar to ketoconazole, fluconazole also has a mature supply chain with broad global manufacturing.

The mature nature of the ketoconazole supply chain generally implies a lower risk profile in terms of availability compared to newer antifungal agents. However, specific supplier risks remain a critical consideration.

What is the typical lead time for ketoconazole API orders?

Lead times for ketoconazole API orders can vary significantly based on the supplier's current production schedule, order volume, and logistical factors.

• Standard Orders: For established suppliers and moderate quantities, typical lead times can range from 8 to 16 weeks.
• Large Volume Orders: Substantial orders may require longer lead times as manufacturers need to schedule production campaigns, procure raw materials, and manage batch sizes. This could extend lead times to 16 to 24 weeks or more.
• Expedited Orders: In cases of critical shortage or urgent demand, expedited production and shipping might be possible, but often incur significant premium costs and are subject to supplier capacity.
• Inventory Levels: The availability of finished API stock at the supplier can shorten lead times considerably, potentially to 2 to 4 weeks. However, relying on readily available stock can be precarious if demand spikes.

It is crucial for pharmaceutical companies to maintain strong relationships with their API suppliers and forecast demand accurately to secure timely deliveries.

What is the typical shelf life of ketoconazole API?

Ketoconazole API, when stored under appropriate conditions, typically has a shelf life of 3 to 5 years.

• Storage Conditions: Manufacturers recommend storage in tightly sealed containers, protected from light and moisture, at controlled room temperatures. Specific temperature ranges (e.g., 20°C to 25°C or 15°C to 30°C) are usually detailed in the Certificate of Analysis (CoA).
• Stability Studies: Manufacturers conduct extensive stability studies to determine the retest period or expiry date of the API. These studies assess degradation under various stress conditions (heat, humidity, light).
• Retest Period vs. Expiry Date: Some suppliers provide a "retest period," after which the API should be re-analyzed to confirm its continued suitability for use. Others provide an "expiry date."
• Impact of Improper Storage: Deviation from recommended storage conditions can significantly shorten the effective shelf life and compromise API quality.

Key Takeaways

• Ketoconazole API manufacturing is primarily concentrated in China and India, with Europe and North America playing secondary roles.
• Major suppliers include Symbiotec Pharmachem, Abbott India, Divi's Laboratories, Hubei Guangji Pharmaceutical, Zhejiang NHU, Shandong Xinhua Pharmaceutical, and Bayer AG.
• Regulatory compliance, particularly cGMP, DMF submission, and adherence to pharmacopoeial standards, is critical for API sourcing.
• Supply chain risks include geopolitical instability, regulatory changes, quality failures, raw material shortages, and logistical disruptions.
• The ketoconazole supply chain is mature, offering generally stable availability and cost-effectiveness compared to newer antifungal agents.
• Typical lead times for ketoconazole API orders range from 8 to 24 weeks, influenced by order volume and supplier inventory.
• Ketoconazole API generally has a shelf life of 3 to 5 years when stored under recommended conditions.

FAQs

1. What is the primary regulatory requirement for importing ketoconazole API into the United States? The primary regulatory requirement for importing ketoconazole API into the United States is compliance with FDA's cGMP regulations. Importers must ensure the API is manufactured in a facility that meets these standards, and the manufacturer should have a relevant Drug Master File (DMF) on record with the FDA.

2. How does the cost of ketoconazole API compare to newer azole antifungals like posaconazole? Ketoconazole API is generally significantly less expensive than posaconazole API. This cost difference is due to ketoconazole's mature manufacturing processes, broad supplier base, and longer patent exclusivity history compared to the more complex synthesis and newer market introduction of posaconazole.

3. What are the key quality parameters that pharmaceutical companies verify when sourcing ketoconazole API? Pharmaceutical companies verify key quality parameters including identity, purity (assay), impurity profile (related substances, residual solvents, heavy metals), microbial limits, and physical characteristics (e.g., particle size distribution, polymorphism) against pharmacopoeial standards (USP, Ph. Eur.) and agreed-upon specifications.

4. Can a pharmaceutical company use multiple API suppliers for ketoconazole to mitigate risk? Yes, using multiple qualified API suppliers is a common strategy to mitigate supply chain risk. This requires each supplier to undergo rigorous qualification, and the pharmaceutical company must manage differences in manufacturing processes and quality attributes between suppliers.

5. What is the typical impact of a major environmental regulation change in China on ketoconazole API supply? A major environmental regulation change in China can lead to temporary or permanent closure of non-compliant API manufacturing facilities, reduced production output due to stricter waste management or emission controls, and increased production costs for compliant facilities. This can result in price increases and potential supply shortages for ketoconazole API sourced from China.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/developmentapprovalprocess/formssubmissionguidancerequirements/drugmasterfiles/ [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/good-manufacturing-practice-gmp [3] United States Pharmacopeia. (n.d.). General Chapters. In United States Pharmacopeia and National Formulary. Retrieved from https://www.usp.org/ [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). The European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia [5] European Chemicals Agency. (n.d.). REACH. Retrieved from https://echa.europa.eu/regulations/reach [6] Symbiotec Pharmachem Pvt. Ltd. (n.d.). Products. Retrieved from https://www.symbiotecpharmachem.com/products/ [7] Divi's Laboratories Limited. (n.d.). APIs. Retrieved from https://www.divis.com/ [8] Hubei Guangji Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from https://www.guangjipharmaceutical.com/ [9] Zhejiang NHU Co., Ltd. (n.d.). Product Information. Retrieved from https://www.nuolin.com/ [10] Shandong Xinhua Pharmaceutical Co., Ltd. (n.d.). Product Center. Retrieved from https://www.xhzy.com/